245 related articles for article (PubMed ID: 38252832)
21. Recent advances on drug delivery nanocarriers for cerebral disorders.
Zhou Z; Sun T; Jiang C
Biomed Mater; 2021 Feb; 16(2):024104. PubMed ID: 33455956
[TBL] [Abstract][Full Text] [Related]
22. Nanocarriers Call the Last Shot in the Treatment of Brain Cancers.
Mehrabian A; Mashreghi M; Dadpour S; Badiee A; Arabi L; Hoda Alavizadeh S; Alia Moosavian S; Reza Jaafari M
Technol Cancer Res Treat; 2022; 21():15330338221080974. PubMed ID: 35253549
[TBL] [Abstract][Full Text] [Related]
23. Nano-enabled delivery systems across the blood-brain barrier.
Hwang SR; Kim K
Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
[TBL] [Abstract][Full Text] [Related]
24. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
Sa P; Singh P; Dilnawaz F; Sahoo SK
Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
[TBL] [Abstract][Full Text] [Related]
25. Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier.
Nafee N; Gouda N
Curr Gene Ther; 2017; 17(2):154-169. PubMed ID: 28494740
[TBL] [Abstract][Full Text] [Related]
26. [Research progress on liposome and nanomicelle targeted drug delivery system across blood-brain barrier].
Yang X; Zou LH; Ding WY; Zhang ZB; Chen JQ; Li JL; Feng HL; Li YY; Tang L; Feng JF
Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(22):5965-5977. PubMed ID: 36471922
[TBL] [Abstract][Full Text] [Related]
27. Emerging strategies to fabricate polymeric nanocarriers for enhanced drug delivery across blood-brain barrier: An overview.
Song YH; De R; Lee KT
Adv Colloid Interface Sci; 2023 Oct; 320():103008. PubMed ID: 37776736
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-)clinical studies with an emphasis on vesicles.
Poustforoosh A; Nematollahi MH; Hashemipour H; Pardakhty A
J Control Release; 2022 Mar; 343():777-797. PubMed ID: 35183653
[TBL] [Abstract][Full Text] [Related]
29. Overcoming the blood-brain barrier? - prediction of blood-brain permeability of hydrophobically modified polyethylenimine polyplexes for siRNA delivery into the brain with in vitro and in vivo models.
Hartl N; Gabold B; Adams F; Uhl P; Oerter S; Gätzner S; Metzger M; König AC; Hauck SM; Appelt-Menzel A; Mier W; Fricker G; Merkel OM
J Control Release; 2023 Aug; 360():613-629. PubMed ID: 37437848
[TBL] [Abstract][Full Text] [Related]
30. Covalent nano delivery systems for selective imaging and treatment of brain tumors.
Ljubimova JY; Sun T; Mashouf L; Ljubimov AV; Israel LL; Ljubimov VA; Falahatian V; Holler E
Adv Drug Deliv Rev; 2017 Apr; 113():177-200. PubMed ID: 28606739
[TBL] [Abstract][Full Text] [Related]
31. In vivo monitoring blood-brain barrier permeability using spectral imaging through optical clearing skull window.
Feng W; Zhang C; Yu T; Semyachkina-Glushkovskaya O; Zhu D
J Biophotonics; 2019 Apr; 12(4):e201800330. PubMed ID: 30485699
[TBL] [Abstract][Full Text] [Related]
32. Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption.
Janowicz PW; Houston ZH; Bunt J; Fletcher NL; Bell CA; Cowin G; Howard CB; Taslima D; Westra van Holthe N; Prior A; Soh V; Ghosh S; Humphries J; Huda P; Mahler SM; Richards LJ; Thurecht KJ
Biomaterials; 2022 Apr; 283():121416. PubMed ID: 35217483
[TBL] [Abstract][Full Text] [Related]
33. Perspectives on Nanodelivery to the Brain: Prerequisites for Successful Brain Treatment.
Hu Y; Hammarlund-Udenaes M
Mol Pharm; 2020 Nov; 17(11):4029-4039. PubMed ID: 33064009
[TBL] [Abstract][Full Text] [Related]
34. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease.
Yin T; Yang L; Liu Y; Zhou X; Sun J; Liu J
Acta Biomater; 2015 Oct; 25():172-83. PubMed ID: 26143603
[TBL] [Abstract][Full Text] [Related]
35. Overcoming the Blood-Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours.
Ferraris C; Cavalli R; Panciani PP; Battaglia L
Int J Nanomedicine; 2020; 15():2999-3022. PubMed ID: 32431498
[TBL] [Abstract][Full Text] [Related]
36. Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers.
Poovaiah N; Davoudi Z; Peng H; Schlichtmann B; Mallapragada S; Narasimhan B; Wang Q
Nanoscale; 2018 Sep; 10(36):16962-16983. PubMed ID: 30182106
[TBL] [Abstract][Full Text] [Related]
37. Rational nanocarrier design towards clinical translation of cancer nanotherapy.
Guo D; Ji X; Luo J
Biomed Mater; 2021 Mar; 16(3):. PubMed ID: 33540386
[TBL] [Abstract][Full Text] [Related]
38. A filter-free blood-brain barrier model to quantitatively study transendothelial delivery of nanoparticles by fluorescence spectroscopy.
De Jong E; Williams DS; Abdelmohsen LKEA; Van Hest JCM; Zuhorn IS
J Control Release; 2018 Nov; 289():14-22. PubMed ID: 30243824
[TBL] [Abstract][Full Text] [Related]
39. In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice.
Stojanov K; Georgieva JV; Brinkhuis RP; van Hest JC; Rutjes FP; Dierckx RA; de Vries EF; Zuhorn IS
Mol Pharm; 2012 Jun; 9(6):1620-7. PubMed ID: 22536790
[TBL] [Abstract][Full Text] [Related]
40. Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier.
Marcos-Contreras OA; Greineder CF; Kiseleva RY; Parhiz H; Walsh LR; Zuluaga-Ramirez V; Myerson JW; Hood ED; Villa CH; Tombacz I; Pardi N; Seliga A; Mui BL; Tam YK; Glassman PM; Shuvaev VV; Nong J; Brenner JS; Khoshnejad M; Madden T; Weissmann D; Persidsky Y; Muzykantov VR
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3405-3414. PubMed ID: 32005712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
